<DOC>
	<DOCNO>NCT02275416</DOCNO>
	<brief_summary>This study , 20 patient participate , examine safety tolerability ipilimumab/UV1 combination patient unresectable metastatic malignant melanoma .</brief_summary>
	<brief_title>Safety UV1 Vaccination Combination With Ipilimumab Patients With Unresectable Metastatic Malignant Melanoma</brief_title>
	<detailed_description>This phase I/IIa , national , open label , single arm , interventional study examine safety tolerability ipilimumab/UV1 combination patient unresectable metastatic malignant melanoma . Patients sign informed consent form ask take part study . All patient receive ipilimumab together UV1 vaccine rranulocyte-macrophage colony-stimulating factor ( GM-CSF ) . Ipilimumab give every 3rd week total 4 dos . The UV1 vaccine GM-CSF give treatment ipilimumab . The maximum number UV1/GM-CSF 10 dos . Immunoresponders maybe follow every third month 5 year first UV1 treatment . Follow-up onging .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis unresectable metastatic malignant melanoma , include cutaneous , ocular , mucosal unknown primary tumour . 2 . Unresectable Stage III Stage IV melanoma ( AJCC 2010 ) 3 . Prior adjuvant melanoma therapy permit ; number previous treatment melanoma permit . 4 . ECOG performance status 0 1 ( see Error ! Reference source found. ) . 5 . Men woman ≥ 18 year age 6 . Adequate hematologic , renal hepatic function , specifically : 1 . WBC ≥ 2500/μL 2 . Absolute neutrophil count ( ANC ) ≥ 1000/uL 3 . Platelets ≥ 75 x 103/μL 4 . Haemoglobin ≥ 9 g/dL 5 . Creatinine ≤ 2.5 x ULN 6 . AST/ALT ≤ 3 x ULN patient without liver metastasis ; ≤ 5 x ULN patient liver metastasis 7 . Total bilirubin ≤ 3 x ULN , ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) 7 . Women childbearing potential men must use acceptable method describe protocol prevent pregnancy . 8 . Signed informed consent expect cooperation patient treatment follow must obtain document accord ICH GCP , national/local regulation . 1 . History current active autoimmune disease , include limited inflammatory bowel disease , rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic sclerosis ( scleroderma variant ) , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy ( e.g . GuillainBarre syndrome ) . Patients vitiligo exclude . 2 . MRI detect active brain metastasis witch require therapy surgery and/or radiation therapy . Patients already treat brain metastasis , surgery radiation therapy , stable disease two month NOT require steroid may however include study . 3 . Uncontrolled infectious disease require negative test clinically suspect human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 4 . History current immunodeficiency disease , splenectomy splenic irradiation 5 . Prior allogeneic stem cell transplantation 6 . Pregnancy 7 . Women breastfeed 8 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation Adverse Events , condition associate frequent diarrhoea 9 . History allergic reaction parenteral administer recombinant protein product 10 . History another malignancy opinion investigator may compromise outcome study 11 . Any reason , opinion investigator , patient participate . 12 . Known serious reaction hypersensitivity component UV1 vaccine similar peptide base vaccine 13 . Known hypersensitivity GMCSF 14 . Known hypersensitivity excipients investigational product 15 . Concomitant use antithrombotic agent exception platelet inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>